title: Induction of a novel mechanism of accelerated bacterial clearance by lipopolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice.
abstract: Despite the lack of a proinflammatory response to LPS, CD14-deficient mice clear Gram-negative bacteria (Escherichia coli 0111) at least 10 times more efficiently than normal mice. In this study, we show that this is due to an early and intense recruitment of neutrophils following the injection of Gram-negative bacteria or LPS in CD14-deficient mice; in contrast, neutrophil infiltration is delayed by 24 h in normal mice. Similar results of early LPS-induced PMN infiltration and enhanced clearance of E. coli were seen in Toll-like receptor (TLR) 4-deficient mice. Furthermore, the lipid A moiety of LPS induced early neutrophil infiltration not only in CD14-deficient and TLR-4-deficient mice, but also in normal mice. In conclusion, the lipid A component of LPS stimulates a unique and critical pathway of innate immune responses that is independent of CD14 and TLR4 and results in early neutrophil infiltration and enhanced bacterial clearance.
authors.affiliation: Division of Molecular Medicine, North Shore University Hospital/New York University School of Medicine, Manhasset, NY 11030, USA.
authors.forename: A
authors.initials: A
authors.lastname: Haziot
authors.forename: N
authors.initials: N
authors.lastname: Hijiya
authors.forename: S C
authors.initials: SC
authors.lastname: Gangloff
authors.forename: J
authors.initials: J
authors.lastname: Silver
authors.forename: S M
authors.initials: SM
authors.lastname: Goyert
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D006224:Cricetinae; D029721:Drosophila Proteins; D004926:Escherichia coli / Q000276:immunology; D004927:Escherichia coli Infections / Q000235:genetics / Q000276:immunology* / Q000382:microbiology* / Q000517:prevention & control; D007274:Injections, Intraperitoneal; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018950:Lipopolysaccharide Receptors / Q000235:genetics* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000737:chemistry; D008562:Membrane Glycoproteins / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020556:Neutrophil Infiltration / Q000235:genetics / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D011956:Receptors, Cell Surface / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors
chemical_list: D000276:Adjuvants, Immunologic; D029721:Drosophila Proteins; D008050:Lipid A; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; C085483:Re lipopolysaccharide; D011956:Receptors, Cell Surface; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; C048436:monophosphoryl lipid A